Drug Profile
Estradiol topical - CapaVision/Redwood Pharma
Alternative Names: 17-beta estradiolLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator CAPA Vision
- Developer CAPA Vision; Redwood Pharma
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for clinical-Phase-Unknown development in Dry-eyes in United Kingdom (Topical, Suspension)
- 23 Jul 2020 The US Patent and Trademark Office issues a notice of allowance for a patent covering the use of estrogens for the treatment of Dry eyes
- 16 Mar 2018 CAPA VISION has patents pending for estrogen topical in USA, Europe and world before March 2018